Targovax ASA: ONCOS-102 achieves 25.0 months median overall survival in first line mesothelioma

OSLO, Norway, Dec. 20, 2021. Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces mOS of 25.0 months for treatment with ONCOS-102 in combination with...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials